Association of Fat mass and obesity gene (FTO) polymorphism with COVID-19 severity in Egyptian obese patients

Walaa M Sarhan*, Nahla Zidan **, Abeer El-Hawary***, Nagwan A. Ismail***, Vishruti Makani****, Hanim M. Abdel-nour *
*Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
** Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
*** Chest Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
**** Process Development Scientist, KBI Biopharma, Durham, NC, US

* Corresponding author:
Walaa Mohamed Sarhan
Email: walaasarhan@hotmail.com

Submit Date 2021-06-12
Revise Date 2021-06-15
Accept Date 2021-06-16

1-ABSTRACT

Background: Fat mass and obesity gene (FTO) polymorphism had linked with risks and health problems related to obesity in many studies and different population. Our study was designed to investigate association of FTO rs9939609 with COVID-19 severity and biochemical parameters such as serum triacylglycerol, cholesterol, transaminases and plasma glucose in obese Egyptian population.

Methods: TaqMan SNP Genotyping Assay of FTO gene rs9939609 (A < T) in a sum of 253 obese cases infected with COVID-19. Fasting samples of serum insulin, plasma glucose, lipid profile, as well as ALT and AST were measured. Evaluation of the association between COVID-19 severity and genotype distribution was done via logistic regression tests and Chi-square.

Results: The association of COVID-19 severity with genotype distribution was significant (χ² = 8.6/P = 0.014) and odds ratio under dominant model (OR = 1.86, P = 0.029 and 95%C.I = 1.08-3.4) and recessive model (OR = 2.95,P = 0.017 and 95%C.I = 1.23-6.42) was increased. HDL-C levels in (AA) subjects (P = 0.009) were significantly lower in comparison to (TT). Moreover, ALT levels in (AA) genotype subjects (P = 0.02) were significantly higher and persisted in accordance with correction of major confusing parameters as TAG and BMI, while aborted with conservative Bonferroni adjustment.

Conclusions: The current study displayed that Fat mass and obesity gene (FTO) rs9939609 is a risk factor for COVID-19 severity in obese individuals that may aid to understand the pathophysiology of the disease progression and highlighted that lipid metabolism may play a role in this association.

Keywords: Alt, COVID-19, FTO, HDL-c, Serum lipid, SNP, Obesity.

2. INTRODUCTION

A new beta coronavirus has been identified as the causing pathogen for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1]. The target organ for COVID-19 is the lung but affects other organs as well, causing multi-organ negative consequences [1,2].

Three stages have been observed in COVID-19 patients, with reference to progression and extent: (i) “mild” which occurs in the vast majority of patients with minor symptoms and don’t progress to severe disease; (ii) “moderate” these are hospitalized patients suffering from pneumonia on radiology accompanied with symptoms or laboratory lymphopenia or leukopenia; and (iii) “severe” who were admitted to the Intensive Care Unit due to systemic hyper-inflammatory status and ARDS and at risk of fatal outcome [3,4].

Regardless of various targeted and non-targeted method for management, no specific treatment has yet been proven effective in treating COVID-19.

Fat mass and obesity (FTO), or alpha-ketoglutarate-dependent dioxygenase, is a
sample nominee gene for obesity with genome wide association evidence [5]. Many studies featured the association of this gene polymorphism with obesity in Egyptian population and others [6-11]. FTO variant rs9939609 (first intronic one) was specifically selected to current study because of its unique genotyping successful rate which is the highest compared to other risk single nucleotide polymorphisms related to obesity as well as its proved powerful genome wide association with obesity according to evidence-based studies [5]. Moreover, although this variant is not the true functional one, there is high probability that it is linked to disequilibrium with true functional variants in FTO gene or nearby genes [10]. Various studies showed that the obese patients were vulnerable to risk of having severe COVID-19 [12-14]. Thus, current study was purposed for the investigation of FTO gene rs9939609 association with the degree of COVID-19 severity and its endophenotypes in Egyptian obese patients.

2. Methods

2.1. Patients and Samples
A total of random unrelated 253 COVID-19 patients were studied. They were recruited from Faculty of Medicine, Zagazig University, Egypt. The sample included 118 males and 135 females, of mean age ± SD (41 ± 15.3). Written informed consent was obtained from all participants, the study was approved by the research ethical committee of Faculty of Medicine, Zagazig University. The study was done according to The Code of Ethics of the World Medical Association (Declaration of Helsinki) for studies involving humans. Obesity was determined in accordance to anthropometric measures (body mass index > 30 kg/m and waist circumference ≥ 80 cm). They were sub grouped according to severity in reference to MOHP (Ministry Of Health & Population) Protocol:

- 1st GROUP (Severe cases): with 124 patients, who were admitted to the ICU (Intensive Care Unit) due to COVID-19 serious consequences.
- 2nd GROUP (Mild cases): comprised 129 patients, the patients were considered as mild cases if they show symptoms with no radiological evidence for pneumonia with lymphopenia or leukopenia. And they were asked for home quarantine with follow up. Detailed history taking, anthropometric measures, vital signs, and full medical evaluation were done for every case. Informed consents were obtained before inclusion in our study. Participants with any medical condition that may deceive the study results were excluded.

2.2. Blood sampling

After overnight fasting for (12 hours), samples (7-10 ml) of morning blood were collected. Separate collection of samples was done as follows: one whole blood sample (3 ml) with disodium-ethlenediamine tetra-acetic acid (EDTA) for DNA extraction. Another one was directed to serum collection aliquots to measure fasting insulin, lipid profile, ALT & AST. The last one was fluoride containing to collect plasma for fasting plasma glucose measuring. Lipid profile and plasma glucose rates were checked instantly; while, we froze other samples were instantly at (− Eighty °C) till sequent tests were performed.

2.3. Anthropometric and biochemical measurements

Body Mass Index (BMI) and Waist Circumference (WC) represented the anthropometric measurements. Plasma glucose which was checked using automated biochemistry analyzer - Dimension RxL analyzer (Dade Behring, Newark, DE). Autoanalyser (Beckman synchron cx systems) was used for measuring aspartate aminotransferase (AST) and alanine aminotransferase (ALT), serum total cholesterol (TC), triacylglycerol (TAG) and high- density lipoprotein (HDL) cholesterol, while, Friedewald formula was used for Low-density lipoprotein (LDL) calculation [15]. ELISA kit (Immunospec® kit, provided from Immunospec Corporation, Canoga Park, CA, USA) was used for measuring serum insulin. Insulin resistance was measured using Homeostasis model assessment (HOMA-IR) - calculation: [(FBG X fasting insulin)/405] [16] and Quantitative insulin sensitivity check
(FTO) gene polymorphism in COVID-19

Sarhan W., et al

DOI: 10.21608/zunj.2021.80189.2260

index (QUICKI) - calculation: 1/[log FI (μIU/ml) + log FBG (mg/dl)] [17]. All these represented the Biochemical measurements.

2.4. Genotyping
QIAamp DNA Mini Kit protocol (QIAGEN, Santa Clarita, CA) was used for DNA extraction. Then, extracted DNA was stored at −80 °C until used for genotyping assay. TaqMan SNP Genotyping Assays (ABI; Applied Biosystems international, Foster City, CA) using Real-Time PCR System (The Applied Biosystems® Step One PlusTM) was used for performing FTO gene genotyping rs9939609 (A < T). To assure genotyping reproducibility, 20% selections of the samples were re-genotyped with 100% concordance.

2.5. Statistical analysis
Data were analyzed using the IBM SPSS for Mac version 23. Numeric variables were expressed as (Mean ± SD), numeric nonparametric variables as (median and range), and categorical variables as (number and percentage).

Independent Student’s t-test (numeric parametric variables) and Mann-Whitney's U-test (numeric non-parametric variables) were used for analysis of difference between the two groups. While the one-way analysis of variance (ANOVA) was used for comparisons between the three groups with respect to normally distributed numeric variables. We used Bonferroni post hoc for the pair compare for significant tests. We used Bonferroni post hoc and The Kruskal- Wallis tests for groups’ comparison concerning numeric variables with abnormal distribution. We used Chi-square test for groups comparison concerning categorical data. We applied Conservative Bonferroni adjustment for considerable tests (High-density lipoprotein cholesterol and Alanine aminotransferase) to avert multiple testing error (adjusted p value at 0.01).

We compared allele frequency and Genotype distributions with the (χ2) test and computed Hardy-Weinberg equilibrium by online calculator. We performed Logistic regression for evaluation of associations of rs 9,939,609 single-nucleotide polymorphism with severity of COVID-19 (odds ratio was calculated as well as their adjusted values for age with their ninety fifth percentile confidence interval and congruent p-value). We used multiple regression models to study FTO polymorphism association with levels of alanine aminotransferase after correction of serum triglycerides and body mass index.

3. RESULTS
‘Table 1’, shows a considerable difference in both biochemical and anthropometric measurements among our study groups. Fasting plasma glucose (FPG), serum triacylglycerols (TAG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), body mass index (BMI) and waist circumference (WC) were significantly higher, while high-density lipoprotein cholesterol (HDL-C) level was lower in the severe COVID-19 group versus mild and moderate groups.

As shown in ‘Table 2’. In the whole studied group, the distribution of genotype for rs 9,939,609 variant was 52.8% TA, 34% TT, and 13.2% AA. Severe group versus mild group genotype distribution was 54.2% TA, 24.1% TT, and 21.7% AA versus 53.4% TA, 42% TT, and 4.6% AA successively.

As depicted in ‘Table 2’, the association of genotype distribution with COVID-19 severity was significant (χ2 = 8.6/P = 0.014), the dominant genetic model was increased by 1.86-fold in the odds of severe COVID-19 cases (95% C.I = 1.08–3.4, p = 0.029). The AA genotype was increased by 2.95-fold in the odds of severe COVID-19 cases (95% C.I = 1.23–6.42, p = 0.017) regarding recessive genetic model.

For high-density lipoprotein cholesterol (HDL-C) levels and Alanine aminotransferase (ALT), we found no significant difference in biochemical and anthropometric measurements of studied sample at all models (dominant, additive, & recessive) among different genotypes. as regards to high density lipoprotein cholesterol (HDL-C), significant lower (P = 0.009) levels of AA genotype were shown and it was interesting that levels persisted significant after conservative Bonferroni adjustment. As regards to Alanine aminotransferase (ALT), significant higher (P = 0.02) levels of AA carriers were shown, as mentioned in ‘Table 3’. After correction of serum TAG and BMI the significant
association remained, but after using the multiple testing this association was conservative Bonferroni adjustment for eliminated.

Table 1 Characteristics of severe cases (n = 124), and mild cases (n = 129)

<table>
<thead>
<tr>
<th></th>
<th>Group I Severe cases (N = 124)</th>
<th>Group II Mild cases (N = 129)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean ± S.D</td>
<td>51.8 ± 16.4</td>
<td>38.5 ± 14.9</td>
<td>0.130^c</td>
</tr>
<tr>
<td>BMI, Kg/m^2, mean ± S.D</td>
<td>37.64 ± 5.4</td>
<td>24.64 ± 5.3</td>
<td>&lt;0.001^a</td>
</tr>
<tr>
<td>Waist (cm), mean ± S.D</td>
<td>119.66 ± 10.66</td>
<td>78.66 ± 9.2</td>
<td>&lt;0.001^a</td>
</tr>
<tr>
<td>TC (mg/dl), mean ± S.D</td>
<td>182.11 ± 44.51</td>
<td>140.01 ± 34.21</td>
<td>&lt;0.001^a</td>
</tr>
<tr>
<td>TAG (mg/dl), mean ± S.D</td>
<td>176.44 ± 84.16</td>
<td>140.44 ± 44.13</td>
<td>&lt;0.001^a</td>
</tr>
<tr>
<td>HDL-C (mg/dl), mean ± S.D</td>
<td>38.51 ± 9.32</td>
<td>44.76 ± 8.07</td>
<td>&lt;0.001^a</td>
</tr>
<tr>
<td>LDL-C (mg/dl), mean ± S.D</td>
<td>107.11 ± 38.44</td>
<td>98.48 ± 18.32</td>
<td>0.034^a</td>
</tr>
<tr>
<td>FPG (mg/dl), median (min-max)</td>
<td>161(64-361)</td>
<td>89(60-323)</td>
<td>&lt;0.001^b</td>
</tr>
<tr>
<td>FSI (μIU/mL), median (min-max)</td>
<td>13.29(2.9–30.2)</td>
<td>8.5(1-28)</td>
<td>&lt;0.001^b</td>
</tr>
<tr>
<td>HOMA-IR, median (min-max)</td>
<td>4.58(0.67–20.44)</td>
<td>1.9(0.2-23.82)</td>
<td>&lt;0.001^b</td>
</tr>
<tr>
<td>QUICKI, mean ± S.D</td>
<td>0.31 ± 0.14</td>
<td>0.35 ± 0.05</td>
<td>&lt;0.001^a</td>
</tr>
<tr>
<td>FTO (rs9939609)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT, n(%)</td>
<td>24 (24.1)</td>
<td>43 (42)</td>
<td></td>
</tr>
<tr>
<td>AT, n(%)</td>
<td>49 (54.2)</td>
<td>54 (53.4)</td>
<td></td>
</tr>
<tr>
<td>AA, n(%)</td>
<td>19 (21.7)</td>
<td>8 (4.6)</td>
<td></td>
</tr>
</tbody>
</table>

Values are mean ± SD for parametric variables or median (range) for non-parametric variables.

Independent T- test, Mann–Whitney U test, Chi-square test, all with (two-sided p value >0.05 non-significant)

Table 2 Fat mass and obesity gene (FTO) genotypes and COVID-19 severity association

| Dominant Genetic Model     | Reference 1.86 | Reference 1.08, 3.4 | 0.029 |
|                           |                |                    |       |
| Recessive Genetic Model   | Reference 2.95 | Reference 1.23, 6.42| 0.017 |

Logistic regression employed for calculation of ORs, 95% CIs, and p values.
Table 3 Fat mass and obesity (rs9939609) polymorphism association with patients’ clinical characteristics and biochemical measures

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>FTO (rs9939609) Genotypes</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TT (n = 87)</td>
<td>AT (n = 114)</td>
</tr>
<tr>
<td>Age, years, mean ± S.D.</td>
<td>42.3 ± 7.6</td>
<td>44.12 ± 9.7</td>
</tr>
<tr>
<td></td>
<td>0.27 a</td>
<td></td>
</tr>
<tr>
<td>BMI, Kg/m², mean ± S.D.</td>
<td>32±5</td>
<td>30.36 ± 7.1</td>
</tr>
<tr>
<td></td>
<td>0.52 a</td>
<td></td>
</tr>
<tr>
<td>Waist (cm), mean ± S.D.</td>
<td>101.2 ± 20.1</td>
<td>102.3 ± 19.1</td>
</tr>
<tr>
<td>TC (mg/dl), mean ± S.D.</td>
<td>176.3 ± 32.1</td>
<td>162.3 ± 34.3</td>
</tr>
<tr>
<td></td>
<td>0.19 a</td>
<td></td>
</tr>
<tr>
<td>TAG (mg/dl), mean ± S.D.</td>
<td>147.3 ± 53.6</td>
<td>128.5 ± 71.8</td>
</tr>
<tr>
<td></td>
<td>0.52 a</td>
<td></td>
</tr>
<tr>
<td>HDL-C (mg/dl), mean ± S.D</td>
<td>43.2 ± 9.3</td>
<td>41.3 ± 7</td>
</tr>
<tr>
<td></td>
<td>0.01 a</td>
<td></td>
</tr>
<tr>
<td>LDL-C (mg/dl), mean ± S.D</td>
<td>104.4 ± 29.6</td>
<td>101.4 ± 31.6</td>
</tr>
<tr>
<td></td>
<td>0.77 a</td>
<td></td>
</tr>
<tr>
<td>FPG (mg/dl), median (min-max)</td>
<td>105(67–313)</td>
<td>99.5(62–363)</td>
</tr>
<tr>
<td>FSI (μIU/mL), median (min-max)</td>
<td>9.5(2.4–28)</td>
<td>9.3(1–29.1)</td>
</tr>
<tr>
<td>HOMA-IR, median (min-max)</td>
<td>3.1 (0.7–23.8)</td>
<td>2 (0.2–21.5)</td>
</tr>
<tr>
<td>QUICKI, mean ± S.D</td>
<td>0.23 ± 0.032</td>
<td>0.33 ± 0.08</td>
</tr>
<tr>
<td>AST (IU/mL), median (min-max)</td>
<td>14(4–52)</td>
<td>12.4(4–62)</td>
</tr>
<tr>
<td></td>
<td>0.18 b</td>
<td></td>
</tr>
<tr>
<td>ALT (IU/mL), median (min-max)</td>
<td>16(4–59)</td>
<td>12(4–56)</td>
</tr>
</tbody>
</table>

ALT alanine aminotransferase, AST aspartate amino-transferase, BMI Body mass index, FPG Fasting plasma glucose, FSI Fasting serum insulin, HDL-C High-density lipoprotein-cholesterol, LDL-C Low-density lipoprotein-cholesterol, TAG Triacylglycerol, TC Total cholesterol, WC Waist circumference

aOne-way ANOVA, bKruskal-Wallis, all with (two-sided p value >0.05 non-significant)

4. DISCUSSION

Our study is the first one designed for investigation of fat mass and obesity gene (FTO) rs9939609 genotype distribution and its association with COVID-19 severity. Obesity effect on COVID-19 severity was declared in many studies. Busetto et al. found that patients with overweight and obesity admitted in a medical ward for severe acute respiratory syndrome coronavirus 2–related pneumonia, despite their younger age, required more frequently assisted ventilation and access to intensive or semi-intensive care units than normal weight patients [19]. Gao et al. concluded that obese patients had increased odds of progressing to severe COVID-19 [12]. AA genotype subjects have higher body mass index and waist circumference in comparison to TA and TT subjects, yet this wasn't statistically significant. This may be related to comparatively small sample size and different effect size in case of body mass index. This is in agreed with 3 former studies that didn't find association of rs9939609 FTO polymorphism with body mass index and/or waist circumference in a small sample size as well [20-22]. Xu et al. found that under recessive model, some metabolic parameters were significantly associated with FTO variations [23]. We assumed that under recessive model, the manifested association in this current study might result from the associated (AA) subjects lowered high-density lipoprotein cholesterol (HDL-C) levels compared to (TT). Those differences may be due to different age, sample size, ethnic group and/or study design.
The Fat mass and obesity gene association with COVID-19 severity may be related to other associated comorbidities such as type 2 diabetes mellitus and obesity [24] in addition to abnormalities of serum lipid [21, 25]. FTO protein linkage to obesity and type 2 diabetes mellitus (T2DM) exact mechanism is still unknown.

Fat mass and obesity (FTO) gene plays an important role in energy homeostasis as it is expressed (highly) in the hypothalamus, [26]. Fat mass and obesity (FTO) gene genetic variants were associated with increased energy intake [22, 27, 28]. According to in vitro studies and bioinformatics FTO encodes for demethylase enzyme for deoxyribonucleic acid and (especially) single strands of Ribonucleic acid nucleotides [26, 29]. There is significant association between DNA methylation state changes and many different diseases and health conditions including obesity [30, 31]. For instance, interestingly folic acid and vitamin B12 maternal levels affected Indian children obesity proving the important association of methylation state in obesity and other disorders [32,33]. DNA methylation epigenetic changes might mediate fat mass and obesity gene linkage with obesity [34]. Furthermore, this gene has a key role in food intake regulation via its effect on hypothalamus and sensing amino acids levels [35]. It was also proved that FTO gene genetic variants are linked to another gene named IRX3; which may explain FTO single nucleotide polymorphisms with type 2 diabetes mellitus and obesity [36]. Wu et al. assumed that the expression of Fat mass and obesity gene was affected by intronic genetic variants like rs9939609, that might alter adipose tissue adipogenesis [37]. Rat model studies with NAFLD (nonalcoholic fatty liver disease) interestingly found that there was increased lipogenesis and oxidative stress when there was overexpression of FTO in liver as well as increased alanine aminotransferase levels [38]. Guan et al. showed that obesity susceptible genes variants were significantly associated with ALT levels, but not fat mass and obesity, dependent or independent of body mass index [39].

We hope that our concluded results will be a beginning for future studies putting on consideration larger sample size.

5. CONCLUSIONS

Our current study investigated for the first time a probable linkage between the fat mass and obesity gene homozygous variant (AA) and the COVID-19 severity in Egyptian patients which may be mediated through high density lipoprotein cholesterol lowered levels as well as the probable role of polymorphism in the complications of COVID-19

Funding

None to declare.

Competing interest

The authors declare that there is no conflict of interests regarding this study.

REFERENCES


The (FTO) gene polymorphism is associated with obesity-related anthropometric traits in an island population from the eastern Atlantic coast of Madagascar.


1. Introduction


2. Methods

2.1. Study Population


2.2. Data Collection

Data were collected using structured questionnaires and anthropometric measurements. Sarhan A., Sentinelli F., Inciardi M., Costacurta D., 2020.

2.3. Statistical Analysis

Statistical analysis was performed using SPSS software. Sarhan A., Sentinelli F., Inciardi M., Costacurta D., 2020.

3. Results

3.1. Demographic Characteristics

The study population consisted of 100 males and 100 females. Sarhan A., Sentinelli F., Inciardi M., Costacurta D., 2020.

3.2. Anthropometric Measurements

Mean body mass index (BMI) was 25.1 kg/m². Sarhan A., Sentinelli F., Inciardi M., Costacurta D., 2020.

3.3. Genetic Analysis

Genotyping was performed using PCR and RFLP methods. Sarhan A., Sentinelli F., Inciardi M., Costacurta D., 2020.

4. Discussion

The results of this study suggest that FTO gene polymorphisms are associated with obesity-related anthropometric traits in the study population from the eastern Atlantic coast of Madagascar. Sarhan A., Sentinelli F., Inciardi M., Costacurta D., 2020.

5. Conclusion

The study highlights the importance of genetic factors in the development of obesity-related anthropometric traits in the study population from the eastern Atlantic coast of Madagascar. Sarhan A., Sentinelli F., Inciardi M., Costacurta D., 2020.

References


(FTO) gene polymorphism in COVID-19


HOW TO CITE